Cabio Biotech (688089.SH) disclosed the interim report for the first half of 2024. The company achieved a revenue of 2... during the reporting period.
According to the semi-annual report for 2024 disclosed by Cabio Biotech (688089.SH), the company achieved a revenue of 0.261 billion yuan, a year-on-year growth of 31.23%. The net income attributable to shareholders of the listed company was 67.889 million yuan, a year-on-year growth of 94.82%. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 53.0071 million yuan, a year-on-year growth of 132.57%. The basic earnings per share was 0.40 yuan/share.